Utama › Kanser Payudara › Nevada › Reno
Kajian klinikal Kanser Payudara di Reno, NV
13 kajian untuk Kanser Payudara sedang mencari peserta di lokasi dalam dan sekitar Reno (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Mengambil pesertaFasa 3
- Cancer Care Specialists, Reno
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Renown Regional Medical Center, Reno
- Saint Mary's Regional Medical Center, Reno
- Carson Tahoe Regional Medical Center, Carson City · 25 mi jauh
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Mengambil pesertaFasa 2
- Cancer Care Specialists, Reno
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Mengambil pesertaFasa 3
- Renown Regional Medical Center ( Site 0041), Reno
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Mengambil pesertaFasa 1/2
- Renown Regional Medical Center, Reno
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Mengambil pesertaFasa 3
- Research Site, Reno
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Mengambil pesertaFasa 3
- Renown Health Medical Oncology, Reno
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Mengambil pesertaKajian pemerhatian
- Cancer Care Specialist of Reno, Reno
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Mengambil pesertaFasa 3
- Renown Regional Medical Center, Reno
- Saint Mary's Regional Medical Center, Reno
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi jauh
- dan 1 lagi
E-Mindfulness Approaches for Living After Breast Cancer
Mengambil pesertaFasa 3
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi jauh
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Mengambil pesertaFasa 3
- Renown Regional Medical Centre, Reno
- Cancer Care Specialists, Reno
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Mengambil pesertaFasa 3
- Renown Regional Medical Center, Reno
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi jauh
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Mengambil pesertaFasa 1
- Renown Regional Medical Center, Reno
Kajian Kanser Payudara di bandar lain
- New York City, NY134 kajian
- Houston, TX126 kajian
- Boston, MA111 kajian
- Nashville, TN80 kajian
- Los Angeles, CA72 kajian
- Edison, NJ68 kajian
- St. Louis, MO64 kajian
- Durham, NC63 kajian
- Queens, NY63 kajian
- Chicago, IL58 kajian
- Philadelphia, PA56 kajian
- Dallas, TX55 kajian
Kajian lain di Reno
- Kanser Paru-paru Bukan Sel Kecil16 kajian
- Kanser Paru-paru9 kajian
- Degenerasi Makula8 kajian
- Atrofi Geografik8 kajian
- Kanser Ovari7 kajian
- Kanser (semua jenis)7 kajian
- Kanser Kolorektal5 kajian
- Leukemia Mieloid Akut5 kajian
- Kanser Metastatik5 kajian
- Kanser Pankreas5 kajian
- Kanser Kolon5 kajian
- Kanser Rektum4 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.